Arvinas Inc (ARVN) Stock AnalysisARVNStock AnalysisArvinas Inc

Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Arvinas Inc is currently a hold. The stock is priced at $9.18, which is below the average analyst price target of $14, indicating potential upside. However, the RSI is at 47.972, suggesting the stock is neither overbought nor oversold, and insider selling has increased by 504.89%, which raises concerns about future performance. The recent FDA approval for VEPPANU and a significant licensing deal indicate positive momentum, but the overall market sentiment and insider activity suggest caution.

3 analysts cover ARVN: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 16.00.